Natera, Inc. (NASDAQ:NTRA - Get Free Report) Director Roelof Botha sold 87,473 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $169.12, for a total value of $14,793,433.76. Following the completion of the sale, the director now owns 1,224,787 shares of the company's stock, valued at $207,135,977.44. This trade represents a 6.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Natera Stock Up 2.9 %
NTRA opened at $174.00 on Thursday. Natera, Inc. has a 52 week low of $55.56 and a 52 week high of $174.15. The business has a fifty day simple moving average of $138.34 and a 200-day simple moving average of $121.65. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.
Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. During the same period last year, the business posted ($0.95) earnings per share. The company's quarterly revenue was up 63.9% on a year-over-year basis. On average, equities analysts predict that Natera, Inc. will post -1.66 earnings per share for the current year.
Wall Street Analyst Weigh In
Trump’s Sending THIS Crypto Higher on Purpose
From Crypto 101 Media | Ad
Discover the coin set to explode before 2025!
Trump could trigger THIS crypto coin…
YES, I WANT THE #1 CRYPTO NOW
A number of equities research analysts have recently issued reports on NTRA shares. Leerink Partners upped their price target on Natera from $140.00 to $150.00 and gave the company an "outperform" rating in a research report on Thursday, October 17th. Piper Sandler upped their price target on Natera from $150.00 to $200.00 and gave the company an "overweight" rating in a research report on Monday, November 18th. TD Cowen upped their price target on Natera from $155.00 to $175.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. BTIG Research increased their price objective on Natera from $125.00 to $135.00 and gave the stock a "buy" rating in a research report on Friday, August 9th. Finally, UBS Group lowered their price objective on Natera from $160.00 to $145.00 and set a "buy" rating for the company in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, Natera currently has an average rating of "Moderate Buy" and an average target price of $140.59.
Get Our Latest Research Report on NTRA
Institutional Trading of Natera
Several hedge funds have recently modified their holdings of the stock. Covestor Ltd raised its stake in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock valued at $47,000 after acquiring an additional 95 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company's stock valued at $55,000 after acquiring an additional 106 shares in the last quarter. CIBC Asset Management Inc raised its stake in shares of Natera by 3.3% in the third quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company's stock valued at $441,000 after acquiring an additional 111 shares in the last quarter. RiverPark Advisors LLC raised its stake in shares of Natera by 3.5% in the third quarter. RiverPark Advisors LLC now owns 3,347 shares of the medical research company's stock valued at $425,000 after acquiring an additional 112 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC raised its stake in shares of Natera by 5.4% in the third quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company's stock valued at $336,000 after acquiring an additional 135 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.
Natera Company Profile
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
